Cargando…
A20 Haploinsufficiency in East Asia
A20, encoded by the TNFAIP3 gene, is a negative regulator of tumor necrosis factor (TNF)-nuclear factor-κB signaling. It was recently demonstrated that A20 haploinsufficiency (HA20), caused by a heterozygous mutation in the TNFAIP3 gene, can present as an early onset autoinflammatory disease resembl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664410/ https://www.ncbi.nlm.nih.gov/pubmed/34899744 http://dx.doi.org/10.3389/fimmu.2021.780689 |
_version_ | 1784613841418584064 |
---|---|
author | Kadowaki, Tomonori Kadowaki, Saori Ohnishi, Hidenori |
author_facet | Kadowaki, Tomonori Kadowaki, Saori Ohnishi, Hidenori |
author_sort | Kadowaki, Tomonori |
collection | PubMed |
description | A20, encoded by the TNFAIP3 gene, is a negative regulator of tumor necrosis factor (TNF)-nuclear factor-κB signaling. It was recently demonstrated that A20 haploinsufficiency (HA20), caused by a heterozygous mutation in the TNFAIP3 gene, can present as an early onset autoinflammatory disease resembling Behçet’s disease (BD). In addition to autoinflammatory symptoms, HA20 was also reported to be associated with autoimmune diseases and immunodeficiency. Because the phenotypes associated with HA20 are broad, with different severities observed even among individuals in the same family with identical mutations, it has been assumed that the symptoms of HA20 may depend on genetic background and environmental factors. In this review, we summarize the characteristics of patients with HA20 in East Asia and compare these with patients in other regions, mainly the USA and Europe. Patients with HA20 in East Asia developed recurrent fever more frequently than patients in other regions, but were less likely to develop typical BD symptoms such as skin rashes and genital ulcers. In addition, patients with HA20 in East Asia had low rates of complication with autoimmune diseases and low autoantibody detection rates. While anti-TNF-α agents were the primary treatments for severe HA20 in East Asia, anti-interleukin-1 agents and Janus kinase inhibitors were also administered in other regions. Future studies will need to establish methods for analyzing the pathophysiology of HA20 and determining optimal treatment strategies for each patient. |
format | Online Article Text |
id | pubmed-8664410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86644102021-12-11 A20 Haploinsufficiency in East Asia Kadowaki, Tomonori Kadowaki, Saori Ohnishi, Hidenori Front Immunol Immunology A20, encoded by the TNFAIP3 gene, is a negative regulator of tumor necrosis factor (TNF)-nuclear factor-κB signaling. It was recently demonstrated that A20 haploinsufficiency (HA20), caused by a heterozygous mutation in the TNFAIP3 gene, can present as an early onset autoinflammatory disease resembling Behçet’s disease (BD). In addition to autoinflammatory symptoms, HA20 was also reported to be associated with autoimmune diseases and immunodeficiency. Because the phenotypes associated with HA20 are broad, with different severities observed even among individuals in the same family with identical mutations, it has been assumed that the symptoms of HA20 may depend on genetic background and environmental factors. In this review, we summarize the characteristics of patients with HA20 in East Asia and compare these with patients in other regions, mainly the USA and Europe. Patients with HA20 in East Asia developed recurrent fever more frequently than patients in other regions, but were less likely to develop typical BD symptoms such as skin rashes and genital ulcers. In addition, patients with HA20 in East Asia had low rates of complication with autoimmune diseases and low autoantibody detection rates. While anti-TNF-α agents were the primary treatments for severe HA20 in East Asia, anti-interleukin-1 agents and Janus kinase inhibitors were also administered in other regions. Future studies will need to establish methods for analyzing the pathophysiology of HA20 and determining optimal treatment strategies for each patient. Frontiers Media S.A. 2021-11-26 /pmc/articles/PMC8664410/ /pubmed/34899744 http://dx.doi.org/10.3389/fimmu.2021.780689 Text en Copyright © 2021 Kadowaki, Kadowaki and Ohnishi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Kadowaki, Tomonori Kadowaki, Saori Ohnishi, Hidenori A20 Haploinsufficiency in East Asia |
title | A20 Haploinsufficiency in East Asia |
title_full | A20 Haploinsufficiency in East Asia |
title_fullStr | A20 Haploinsufficiency in East Asia |
title_full_unstemmed | A20 Haploinsufficiency in East Asia |
title_short | A20 Haploinsufficiency in East Asia |
title_sort | a20 haploinsufficiency in east asia |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664410/ https://www.ncbi.nlm.nih.gov/pubmed/34899744 http://dx.doi.org/10.3389/fimmu.2021.780689 |
work_keys_str_mv | AT kadowakitomonori a20haploinsufficiencyineastasia AT kadowakisaori a20haploinsufficiencyineastasia AT ohnishihidenori a20haploinsufficiencyineastasia |